The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PAVM | -63.61% | -98.61% | -57.5% | -100% |
| S&P | +12.93% | +85.68% | +13.18% | +214% |
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.01M | -99.5% |
| Gross Profit | -$0.07M | 88.4% |
| Gross Margin | -1440.00% | -1377.4% |
| Market Cap | $9.31M | -27.2% |
| Market Cap / Employee | $0.24M | 0.0% |
| Employees | 39 | -63.6% |
| Net Income | -$6.01M | -109.9% |
| EBITDA | -$4.82M | 57.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.10M | 305.6% |
| Accounts Receivable | $0.00M | -81.2% |
| Inventory | 0 | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.82M | -23.4% |
| Short Term Debt | $7.46M | -77.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 9.02% | -58.0% |
| Return On Invested Capital | -3016.89% | -3295.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.90M | 89.9% |
| Operating Free Cash Flow | -$0.90M | 89.9% |
| Metric | Q1 2025 | Q2 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 1.02 | 0.52 | - | ||
| Price to Book | -0.83 | -1.39 | 0.54 | 0.67 | -539.57% |
| Price to Sales | 2.35 | 19.00 | 10.64 | 320.35 | 2262.25% |
| Price to Tangible Book Value | -0.83 | -1.39 | 0.54 | 0.67 | -544.82% |
| Enterprise Value to EBITDA | -7.13 | -12.33 | -7.38 | -6.80 | -11.92% |
| Return on Equity | 20.0% | - | |||
| Total Debt | $31.86M | $9.24M | $9.31M | $9.28M | -73.43% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
